Algert Global LLC Adaptive Biotechnologies Corp Transaction History

Algert Global LLC

$4.25 Billion
Q4 2024

A detailed history of Algert Global LLC transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Algert Global LLC holds 430,514 shares of ADPT stock, worth $3.13 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

430,514

Previous 76,323 464.07%

Holding current value

$3.13 Million

Previous $391,000 560.1%

% of portfolio

0.06%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$4.37 - $6.78 $1.55 Million - $2.4 Million	354,191 Added 464.07%	430,514 $2.58 Million
Q3 2024 Nov 12, 2024	BUY	$3.37 - $5.12 $40,440 - $61,440	12,000 Added 18.66%	76,323 $391,000
Q2 2024 Aug 14, 2024	SELL	$2.34 - $3.96 $241,401 - $408,525	-103,163 Reduced 61.59%	64,323 $233,000
Q4 2023 Feb 14, 2024	SELL	$3.46 - $5.33 $543,078 - $836,591	-156,959 Reduced 48.38%	167,486 $821,000
Q3 2023 Nov 13, 2023	BUY	$5.07 - $8.44 $142,974 - $238,008	28,200 Added 9.52%	324,445 $1.77 Million
Q2 2023 Aug 14, 2023	SELL	$6.19 - $8.78 $450,322 - $638,745	-72,750 Reduced 19.72%	296,245 $1.99 Million
Q1 2023 May 12, 2023	BUY	$7.8 - $10.11 $597,776 - $774,810	76,638 Added 26.21%	368,995 $3.26 Million
Q4 2022 Feb 13, 2023	BUY	$6.26 - $9.34 $366,892 - $547,408	58,609 Added 25.07%	292,357 $2.23 Million
Q3 2022 Nov 15, 2022	SELL	$6.5 - $12.67 $375,615 - $732,161	-57,787 Reduced 19.82%	233,748 $1.66 Million
Q2 2022 Aug 15, 2022	BUY	$6.4 - $14.73 $1.16 Million - $2.67 Million	181,559 Added 165.09%	291,535 $2.36 Million
Q1 2022 May 16, 2022	BUY	$10.12 - $28.9 $1.11 Million - $3.18 Million	109,976 New	109,976 $1.53 Million

Others Institutions Holding ADPT

# of Institutions

224

Shares Held

146M

Call Options Held

19.6K

Put Options Held

27.2K

View Full List

About Adaptive Biotechnologies Corp

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $1.04B
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

More about ADPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.

Account

Algert Global LLC Adaptive Biotechnologies Corp Transaction History